Head & Neck Cancer Symposium

Advances in Head and Neck Cancer:
Immunotherapy and Precision Medicine

Hosted by Boston University
Henry M. Goldman School of Dental Medicine
and the Dana-Farber Cancer Institute

Provided by Boston University School of Medicine

Monday, September 25, 2017, 8 a.m. – 6.30 p.m.
Metcalf Trustee Ballroom, 1 Silber Way, Boston, MA

Registration Prices:

$300 – Physicians/Dentists receiving CME/CE credits
$200 – Scientists/Researchers (not receiving CME/CE credits)
$100 – Students/Residents
$100 – Hygienists/Dental Assistants receiving CE credits

Please register here.

Click here for information on how to submit abstracts for the poster session.

This symposium will bring basic scientists and clinicians together to discuss the latest developments in Head & Neck Cancer research and therapy. The intention of this meeting is to promote interactions between clinicians and researchers from diverse disciplines and to work towards bridging the translational gap. The agenda for the symposium includes a keynote address by Dr. Robert Ferris, a poster session and four panel discussions on Immunotherapy: Checkpoint Regulation, Immunotherapy: Beyond Checkpoint Inhibitors, Precision Medicine Strategies for Cancer and the Microbiome, and Clinical Problems and Challenges.

Breakfast and lunch will be provided, and the symposium will be followed by a reception. Parking is available.

7:30 – 8 a.m. Registration / Exhibits
8 – 8:10 a.m. Welcome & Opening Remarks
Maria Kukuruzinska, PhD, Boston University
Dean Jeffrey W. Hutter, DMD, MEd, Boston University
Robert Haddad, MD, Dana-Farber Cancer Institute
Session 1 Immunotherapy: Checkpoint Regulation
Session Chair: Robert Haddad, MD, Dana-Farber Cancer Institute
8:10 – 8:35 a.m. John Lee, MD, FACS
Sanford Health
8:35 – 9:00 a.m. Scott Strome, MD
University of Maryland
9 – 9:25 a.m. Tanguy Seiwert, MD
University of Chicago
9:25 – 9:40 a.m. Panel Discussion
9:40 – 10:10 a.m. Coffee Break / Poster Session / Exhibits
10:10 – 11:10 a.m. Keynote Presentation
Robert Ferris, MD, PhD, FACS
University of Pittsburgh
Session 2 Immunotherapy: Beyond Checkpoint Inhibitors
Session Chair: Jeffrey Myers, MD, PhD, MD Anderson Cancer Center
11:10 – 11:35 a.m. Dmitry I. Gabrilovich, MD, PhD
The Wistar Institute
11:35 – 12:00 p.m. Ravindra Uppaluri, MD, PhD
Dana-Farber Cancer Institute
12:20 – 12:25 p.m. Andrew Weinberg, PhD
Providence Cancer Center
12:25 a.m. – 12:40 p.m. Panel Discussion
12:40 – 1:45 p.m. Lunch / Exhibits
Session 3 Precision Medicine Strategies for Cancer and the Microbiome
Session Chair: Sara Pai, MD, PhD, Massachusetts General Hospital
1:45 – 2:10 p.m. Ezra Cohen, MD
University of California San Diego
2:10 – 2:35 p.m. Maria Kukuruzinska, PhD
Boston University
2:35 – 3:00 p.m. Jennifer Grandis, MD
University of California San Francisco
3:00 – 3:15 p.m. Panel Discussion
3:15 – 3:45 p.m. Coffee Break / Exhibits
Session 4 Clinical Problems and Challenges
Session Chair: Andrew Salama, DDS, MD, Boston University
3:45 – 4:10 p.m. Richard Wong, MD, FACS
Memorial Sloan Kettering Cancer Center
4:10 – 4:35 p.m. Lori Wirth, MD
Massachusetts General Hospital
4:35 – 5:00 p.m. Barbara Burtness, MD
Yale University
5:00 – 5:15 p.m. Panel Discussion
5:15 – 5:20 p.m. Poster Award Presentation
5:20 – 5:30 p.m. Closing Remarks
5:30 – 6:30 p.m. Reception



Robert Haddad, MD
Disease Center Leader, Head and Neck Oncology Program
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Maria Kukuruzinska, PhD
Professor, Molecular & Cell Biology
Associate Dean for Research
Boston University Henry M. Goldman School of Dental Medicine

Target audience:

  • Otolaryngology / Head and Neck Surgery
  • Medical Oncology
  • Radiation Oncology
  • Surgical Oncology
  • Oral and Maxillofacial Surgery
  • Oral and Maxillofacial Radiology
  • Oral and Maxillofacial Pathology
  • Dental Public Health
  • Head & Neck Cancer Researchers

Learning objectives:

Upon completion of this activity, participants will be able to:

  1. Describe current research on the etiology, pathogenesis, metastasis and treatment of head and neck cancer;
  2. Apply innovative therapeutic approaches to the treatment of head and neck cancer patients with particular emphasis on immunotherapy and precision medicine;
  3. Identify the translational gap whereby advances in research are not translated into clinical applications that directly benefit patient health.

Course Director:

Andrew Salama, DDS, MD, FACS
Assistant Professor, Oral & Maxillofacial Surgery
Director, Advanced Specialty Education Program in Oral & Maxillofacial Surgery
Boston University Henry M. Goldman School of Dental Medicine

To request reasonable accommodations for a disability please notify OCRI@bu.edu in writing, at least two weeks prior to the conference.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Dana-Farber Cancer Institute. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Boston University Henry M. Goldman School of Dental Medicine designates this activity for 7 continuing education credits.


Evans Center for Interdisciplinary Biomedical Research

Henry M. Goldman School of Dental Medicine